Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s00109-009-0510-z.

Title:
Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer | Journal of Molecular Medicine
Description:
TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis upon binding to TRAIL receptors 1 and 2 (TRAIL-R1/DR4 and TRAIL-R2/DR5). TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) have no or only a truncated cytoplasmic death domain. Consequently, they cannot induce apoptosis and instead have been proposed to inhibit apoptosis induction by TRAIL. Agonists for the apoptosis-inducing TRAIL-R1 and TRAIL-R2 are currently tested in clinical trials. To determine the expression pattern of all surface-bound TRAIL receptors and their prognostic clinical value, we investigated tumour samples of 311 patients with breast cancer by immunohistochemistry. TRAIL receptor expression profiles were correlated with clinico-pathological data, disease-free survival and overall survival. TRAIL-R1 was more strongly expressed in better differentiated tumours, and correlated positively with surrogate markers of a better prognosis (hormone receptor status, Bcl-2, negative nodal status), but negatively with the expression of Her2/neu and the proliferation marker Ki67. In contrast, TRAIL-R2 and TRAIL-R4 expression correlated with higher tumour grades, higher Ki67 index, higher Her2/neu expression and a positive nodal status at the time of diagnosis, but with lower expression of Bcl-2. Thus, the TRAIL receptor expression pattern was predictive of nodal status. Patients with grade 1 and 2 tumours, who had TRAIL-R2 but no TRAIL-R1, showed a positive lymph node status in 47% of the cases. Vice versa, only 19% had a positive nodal status with high TRAIL-R1 but low TRAIL-R2. Most strikingly, TRAIL-R4 and -R2 expression negatively correlated with overall survival of breast cancer patients. Although TRAIL-R2 correlated with more aggressive tumour behaviour, mammary carcinoma could be sensitised to TRAIL-R2-induced apoptosis, suggesting that TRAIL-R2 might therefore be used to therapeutically target such tumours. Hence, determination of the TRAIL receptor expression profile may aid in defining which breast cancer patients have a higher risk of lymph node metastasis and worse overall survival and on the other hand will help to guide TRAIL-based tumour therapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

pubmed, google, scholar, article, cancer, cas, breast, trail, trailr, expression, receptor, tumour, apoptosis, prognostic, apoptosisinducing, ligand, carcinoma, res, patients, ganten, receptors, walczak, death, human, sykora, koschny, clin, necrosis, survival, factorrelated, tnfrelated, status, access, cells, privacy, cookies, content, journal, domain, correlated, bcl, herneu, factor, hepatocellular, data, publish, research, search, medicine, significance,

Topics {✒️}

tnf-related apoptosis-inducing ligand month download article/chapter degli-esposti ma putative stem-cell subpopulation apoptosis-inducing trail-r1 induces cancer-specific apoptosis surface-bound trail receptors trail-r2-induced apoptosis node-negative breast cancer node-positive breast cancer related subjects cytotoxic ligand trail full article pdf cd95-mediated apoptosis trail-mediated apoptosis trail-induced apoptosis independent prognostic parameter investigated tumour samples higher tumour grades aggressive tumour behaviour nf-kappab pathway privacy choices/manage cookies apoptosis-mediating receptor higher her2/neu expression trail-r4 expression correlated apoptosis-promoting receptors human hepatocellular carcinoma invasive breast cancer pathological prognostic factors tumor epithelial cells adjuvant tamoxifen treatment inhibit apoptosis induction human breast cancer local growth promoter incomplete death domain breast cell lines van geelen cm van der wall trail receptor dr4 metastatic breast carcinoma human pancreatic cancer breast cancer tissue trail-r2/dr5 trail death receptors antitumour tumour effects molecular medicine aims situ ductal carcinoma hormone receptor status neoplastic breast tissues primary breast cancer

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer
         description:TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis upon binding to TRAIL receptors 1 and 2 (TRAIL-R1/DR4 and TRAIL-R2/DR5). TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) have no or only a truncated cytoplasmic death domain. Consequently, they cannot induce apoptosis and instead have been proposed to inhibit apoptosis induction by TRAIL. Agonists for the apoptosis-inducing TRAIL-R1 and TRAIL-R2 are currently tested in clinical trials. To determine the expression pattern of all surface-bound TRAIL receptors and their prognostic clinical value, we investigated tumour samples of 311 patients with breast cancer by immunohistochemistry. TRAIL receptor expression profiles were correlated with clinico-pathological data, disease-free survival and overall survival. TRAIL-R1 was more strongly expressed in better differentiated tumours, and correlated positively with surrogate markers of a better prognosis (hormone receptor status, Bcl-2, negative nodal status), but negatively with the expression of Her2/neu and the proliferation marker Ki67. In contrast, TRAIL-R2 and TRAIL-R4 expression correlated with higher tumour grades, higher Ki67 index, higher Her2/neu expression and a positive nodal status at the time of diagnosis, but with lower expression of Bcl-2. Thus, the TRAIL receptor expression pattern was predictive of nodal status. Patients with grade 1 and 2 tumours, who had TRAIL-R2 but no TRAIL-R1, showed a positive lymph node status in 47% of the cases. Vice versa, only 19% had a positive nodal status with high TRAIL-R1 but low TRAIL-R2. Most strikingly, TRAIL-R4 and -R2 expression negatively correlated with overall survival of breast cancer patients. Although TRAIL-R2 correlated with more aggressive tumour behaviour, mammary carcinoma could be sensitised to TRAIL-R2-induced apoptosis, suggesting that TRAIL-R2 might therefore be used to therapeutically target such tumours. Hence, determination of the TRAIL receptor expression profile may aid in defining which breast cancer patients have a higher risk of lymph node metastasis and worse overall survival and on the other hand will help to guide TRAIL-based tumour therapy.
         datePublished:2009-08-13T00:00:00Z
         dateModified:2009-08-13T00:00:00Z
         pageStart:995
         pageEnd:1007
         sameAs:https://doi.org/10.1007/s00109-009-0510-z
         keywords:
            TRAIL receptor
            Apoptosis
            Prognosis
            Breast cancer
            Mammary carcinoma
            Molecular Medicine
            Human Genetics
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-009-0510-z/MediaObjects/109_2009_510_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-009-0510-z/MediaObjects/109_2009_510_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-009-0510-z/MediaObjects/109_2009_510_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-009-0510-z/MediaObjects/109_2009_510_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-009-0510-z/MediaObjects/109_2009_510_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-009-0510-z/MediaObjects/109_2009_510_Fig6_HTML.gif
         isPartOf:
            name:Journal of Molecular Medicine
            issn:
               1432-1440
               0946-2716
            volumeNumber:87
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Tom M. Ganten
               affiliation:
                     name:German Cancer Research Center (DKFZ)
                     address:
                        name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
                     name:University Hospital
                     address:
                        name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jaromir Sykora
               affiliation:
                     name:German Cancer Research Center (DKFZ)
                     address:
                        name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
                     name:University Hospital
                     address:
                        name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ronald Koschny
               affiliation:
                     name:German Cancer Research Center (DKFZ)
                     address:
                        name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
                     name:University Hospital
                     address:
                        name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Emanuela Batke
               affiliation:
                     name:University Hospital
                     address:
                        name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sebastian Aulmann
               affiliation:
                     name:University Hospital
                     address:
                        name:Department of Pathology, University Hospital, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ulrich Mansmann
               affiliation:
                     name:University of München
                     address:
                        name:Department of Medical Biometry and Epidemiology, University of München, München, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Wolfgang Stremmel
               affiliation:
                     name:University Hospital
                     address:
                        name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hans-Peter Sinn
               affiliation:
                     name:University Hospital
                     address:
                        name:Department of Pathology, University Hospital, Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Henning Walczak
               affiliation:
                     name:German Cancer Research Center (DKFZ)
                     address:
                        name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
                        type:PostalAddress
                     type:Organization
                     name:Imperial College London
                     address:
                        name:Tumour Immunology Unit, Division of Medicine, Imperial College London, London, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer
      description:TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis upon binding to TRAIL receptors 1 and 2 (TRAIL-R1/DR4 and TRAIL-R2/DR5). TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) have no or only a truncated cytoplasmic death domain. Consequently, they cannot induce apoptosis and instead have been proposed to inhibit apoptosis induction by TRAIL. Agonists for the apoptosis-inducing TRAIL-R1 and TRAIL-R2 are currently tested in clinical trials. To determine the expression pattern of all surface-bound TRAIL receptors and their prognostic clinical value, we investigated tumour samples of 311 patients with breast cancer by immunohistochemistry. TRAIL receptor expression profiles were correlated with clinico-pathological data, disease-free survival and overall survival. TRAIL-R1 was more strongly expressed in better differentiated tumours, and correlated positively with surrogate markers of a better prognosis (hormone receptor status, Bcl-2, negative nodal status), but negatively with the expression of Her2/neu and the proliferation marker Ki67. In contrast, TRAIL-R2 and TRAIL-R4 expression correlated with higher tumour grades, higher Ki67 index, higher Her2/neu expression and a positive nodal status at the time of diagnosis, but with lower expression of Bcl-2. Thus, the TRAIL receptor expression pattern was predictive of nodal status. Patients with grade 1 and 2 tumours, who had TRAIL-R2 but no TRAIL-R1, showed a positive lymph node status in 47% of the cases. Vice versa, only 19% had a positive nodal status with high TRAIL-R1 but low TRAIL-R2. Most strikingly, TRAIL-R4 and -R2 expression negatively correlated with overall survival of breast cancer patients. Although TRAIL-R2 correlated with more aggressive tumour behaviour, mammary carcinoma could be sensitised to TRAIL-R2-induced apoptosis, suggesting that TRAIL-R2 might therefore be used to therapeutically target such tumours. Hence, determination of the TRAIL receptor expression profile may aid in defining which breast cancer patients have a higher risk of lymph node metastasis and worse overall survival and on the other hand will help to guide TRAIL-based tumour therapy.
      datePublished:2009-08-13T00:00:00Z
      dateModified:2009-08-13T00:00:00Z
      pageStart:995
      pageEnd:1007
      sameAs:https://doi.org/10.1007/s00109-009-0510-z
      keywords:
         TRAIL receptor
         Apoptosis
         Prognosis
         Breast cancer
         Mammary carcinoma
         Molecular Medicine
         Human Genetics
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-009-0510-z/MediaObjects/109_2009_510_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-009-0510-z/MediaObjects/109_2009_510_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-009-0510-z/MediaObjects/109_2009_510_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-009-0510-z/MediaObjects/109_2009_510_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-009-0510-z/MediaObjects/109_2009_510_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-009-0510-z/MediaObjects/109_2009_510_Fig6_HTML.gif
      isPartOf:
         name:Journal of Molecular Medicine
         issn:
            1432-1440
            0946-2716
         volumeNumber:87
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Tom M. Ganten
            affiliation:
                  name:German Cancer Research Center (DKFZ)
                  address:
                     name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
                  name:University Hospital
                  address:
                     name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jaromir Sykora
            affiliation:
                  name:German Cancer Research Center (DKFZ)
                  address:
                     name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
                  name:University Hospital
                  address:
                     name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ronald Koschny
            affiliation:
                  name:German Cancer Research Center (DKFZ)
                  address:
                     name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
                  name:University Hospital
                  address:
                     name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Emanuela Batke
            affiliation:
                  name:University Hospital
                  address:
                     name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sebastian Aulmann
            affiliation:
                  name:University Hospital
                  address:
                     name:Department of Pathology, University Hospital, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ulrich Mansmann
            affiliation:
                  name:University of München
                  address:
                     name:Department of Medical Biometry and Epidemiology, University of München, München, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Wolfgang Stremmel
            affiliation:
                  name:University Hospital
                  address:
                     name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hans-Peter Sinn
            affiliation:
                  name:University Hospital
                  address:
                     name:Department of Pathology, University Hospital, Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Henning Walczak
            affiliation:
                  name:German Cancer Research Center (DKFZ)
                  address:
                     name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
                     type:PostalAddress
                  type:Organization
                  name:Imperial College London
                  address:
                     name:Tumour Immunology Unit, Division of Medicine, Imperial College London, London, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Molecular Medicine
      issn:
         1432-1440
         0946-2716
      volumeNumber:87
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:German Cancer Research Center (DKFZ)
      address:
         name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
         type:PostalAddress
      name:University Hospital
      address:
         name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
         type:PostalAddress
      name:German Cancer Research Center (DKFZ)
      address:
         name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
         type:PostalAddress
      name:University Hospital
      address:
         name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
         type:PostalAddress
      name:German Cancer Research Center (DKFZ)
      address:
         name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
         type:PostalAddress
      name:University Hospital
      address:
         name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
         type:PostalAddress
      name:University Hospital
      address:
         name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
         type:PostalAddress
      name:University Hospital
      address:
         name:Department of Pathology, University Hospital, Heidelberg, Germany
         type:PostalAddress
      name:University of München
      address:
         name:Department of Medical Biometry and Epidemiology, University of München, München, Germany
         type:PostalAddress
      name:University Hospital
      address:
         name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
         type:PostalAddress
      name:University Hospital
      address:
         name:Department of Pathology, University Hospital, Heidelberg, Germany
         type:PostalAddress
      name:German Cancer Research Center (DKFZ)
      address:
         name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
         type:PostalAddress
      name:Imperial College London
      address:
         name:Tumour Immunology Unit, Division of Medicine, Imperial College London, London, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Tom M. Ganten
      affiliation:
            name:German Cancer Research Center (DKFZ)
            address:
               name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
               type:PostalAddress
            type:Organization
            name:University Hospital
            address:
               name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:Jaromir Sykora
      affiliation:
            name:German Cancer Research Center (DKFZ)
            address:
               name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
               type:PostalAddress
            type:Organization
            name:University Hospital
            address:
               name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:Ronald Koschny
      affiliation:
            name:German Cancer Research Center (DKFZ)
            address:
               name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
               type:PostalAddress
            type:Organization
            name:University Hospital
            address:
               name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:Emanuela Batke
      affiliation:
            name:University Hospital
            address:
               name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:Sebastian Aulmann
      affiliation:
            name:University Hospital
            address:
               name:Department of Pathology, University Hospital, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:Ulrich Mansmann
      affiliation:
            name:University of München
            address:
               name:Department of Medical Biometry and Epidemiology, University of München, München, Germany
               type:PostalAddress
            type:Organization
      name:Wolfgang Stremmel
      affiliation:
            name:University Hospital
            address:
               name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:Hans-Peter Sinn
      affiliation:
            name:University Hospital
            address:
               name:Department of Pathology, University Hospital, Heidelberg, Germany
               type:PostalAddress
            type:Organization
      name:Henning Walczak
      affiliation:
            name:German Cancer Research Center (DKFZ)
            address:
               name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
               type:PostalAddress
            type:Organization
            name:Imperial College London
            address:
               name:Tumour Immunology Unit, Division of Medicine, Imperial College London, London, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
      name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
      name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
      name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
      name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
      name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
      name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
      name:Department of Pathology, University Hospital, Heidelberg, Germany
      name:Department of Medical Biometry and Epidemiology, University of München, München, Germany
      name:Department of Internal Medicine, University Hospital, Heidelberg, Germany
      name:Department of Pathology, University Hospital, Heidelberg, Germany
      name:Division of Apoptosis Regulation (D040), German Cancer Research Center (DKFZ), Heidelberg, Germany
      name:Tumour Immunology Unit, Division of Medicine, Imperial College London, London, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(164)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

4.55s.